Biostem Technologies Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 26

Employees

  • Stock Symbol
  • BSEM

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $13.74
  • (As of Friday Closing)

Biostem Technologies General Information

Description

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.

Contact Information

Formerly Known As
Caribbean International Holdings, Beverly Hills Ltd Inc, Keynote Acquisition Corp
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 2836 Center Port Circle
  • Pompano Beach, FL 33064
  • United States
+1 (954)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PINX
Vertical(s)
Corporate Office
  • 2836 Center Port Circle
  • Pompano Beach, FL 33064
  • United States
+1 (954)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biostem Technologies Stock Performance

As of 20-Jun-2025, Biostem Technologies’s stock price is $13.74. Its current market cap is $229M with 16.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$13.74 $13.11 $6.95 - $28.26 $229M 16.7M 68.3K -$0.57

Biostem Technologies Financials Summary

As of 31-Dec-2023, Biostem Technologies has a trailing 12-month revenue of $16.7M.

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 85,511 85,511 32,485 15,390
Revenue 16,685 16,685 6,875 4,341
EBITDA (6,933) (6,933) (6,541) (602)
Net Income (7,863) (7,863) (7,193) (1,445)
Total Assets 14,560 14,560 3,466 2,672
Total Debt 4,724 4,724 5,089 4,831
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biostem Technologies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biostem Technologies‘s full profile, request access.

Request a free trial

Biostem Technologies Patents

Biostem Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240408148-A1 Human umbilical compositions and methods for dermal application Pending 07-Jun-2023
US-20250186506-A1 Human umbilical cord composition for treatment of peyronie's disease Pending 11-Jan-2023
US-20240226181-A1 Human umbilical cord composition for treatment of peyronie's disease Pending 11-Jan-2023
EP-4561595-A2 Human umbilical cord compositions and methods for intra-articular therapy Pending 26-Jul-2022
AU-2023315778-A1 Human umbilical cord compositions and methods for intra-articular therapy Pending 26-Jul-2022 A61K35/51
To view Biostem Technologies’s complete patent history, request access »

Biostem Technologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biostem Technologies Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biostem Technologies‘s full profile, request access.

Request a free trial

Biostem Technologies Investments & Acquisitions (8)

Biostem Technologies’s most recent deal was a Merger/Acquisition with ProgenaCare Global. The deal was made on 20-Nov-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ProgenaCare Global 20-Nov-2024 Merger/Acquisition Biotechnology
Auxocell Laboratories 27-Feb-2023 Merger/Acquisition Diagnostic Equipment
Grupo Impulso De Incentivacion Para Nuevas Tecnologías 26-Feb-2018 Merger/Acquisition Biotechnology
Granisol 22-Aug-2016 Corporate Asset Purchase Buildings and Property
TEN Health 18-May-2016 Merger/Acquisition Clinics/Outpatient Services
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Biostem Technologies Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Auxocell Laboratories Cambridge, MA 2008

Biostem Technologies FAQs

  • When was Biostem Technologies founded?

    Biostem Technologies was founded in 2014.

  • Where is Biostem Technologies headquartered?

    Biostem Technologies is headquartered in Pompano Beach, FL.

  • What is the size of Biostem Technologies?

    Biostem Technologies has 26 total employees.

  • What industry is Biostem Technologies in?

    Biostem Technologies’s primary industry is Biotechnology.

  • Is Biostem Technologies a private or public company?

    Biostem Technologies is a Public company.

  • What is Biostem Technologies’s stock symbol?

    The ticker symbol for Biostem Technologies is BSEM.

  • What is the current stock price of Biostem Technologies?

    As of 20-Jun-2025 the stock price of Biostem Technologies is $13.74.

  • What is the current market cap of Biostem Technologies?

    The current market capitalization of Biostem Technologies is $229M.

  • What is Biostem Technologies’s current revenue?

    The trailing twelve month revenue for Biostem Technologies is $16.7M.

  • What is Biostem Technologies’s annual earnings per share (EPS)?

    Biostem Technologies’s EPS for 12 months was -$0.57.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »